๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213

โœ Scribed by Mark T. Pugh; Kathy M. O'Boyle; Anthony G. Molloy; John L. Waddington


Publisher
Springer
Year
1985
Tongue
English
Weight
625 KB
Volume
87
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

โœฆ Synopsis


The effects of the putative selective dopamine D-1 antagonist benzazepine SCH 23390 and of the selective dopamine D-2 antagonist Ro22-2586 on stereotypy induced by the selective D-2 agonist RU24213 were compared. RU24213 (0.5-15 mg/kg) dose-dependently induced stereo-typed behaviour characterised by continuous downward sniffing and locomotion. These responses were antagonised, as expected, by 40-200 micrograms/kg Ro22-2586, but surprisingly blocked by 40-200 micrograms/kg SCH 23390. The selectivities of these compounds for dopamine receptor subtypes were verified in terms of their relative abilities to displace the in vitro binding of 3H-piflutixol to striatal D-1 receptors and of 3H-spiperone to D-2 receptors. As SCH 23390 fails to influence D-2 mediated prolactin secretion or emesis in vivo, there appears to be no significant formation of an active metabolite of SCH 23390 with D-2 antagonist activity. Because SCH 23390 has some affinity for 5-hydroxytryptamine receptors, any effect on the serotonergic behavioural syndrome induced by 10 mg/kg 5-methoxy-N,N-dimethyltryptamine was also studied. The serotonergic responses of hind limb abduction, reciprocal forepaw treading and Straub tail were unaltered after 40-200 micrograms/kg SCH 23390, indicating no significant 5-HT blockade or non-specific depressant action at these doses which might influence the expression of stereotypy. Thus, these data are consistent with blockade of tonic D-1 dopaminergic activity that may influence the expression of behaviours initiated by D-2 dopaminergic stimulation.


๐Ÿ“œ SIMILAR VOLUMES


Attenuation of the locomotor-sensitizing
โœ Roy A. Wise; William A. Carlezon Jr. ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 525 KB

Injections of the selective D, dopamine agonist bromocriptine (5.0 mg/ kg, IP) produced progressively stronger locomotion over 10 days of repeated testing. Concurrent treatment with either the D, antagonist SCH 23390 (0.01 or 0.1 mg/kg, IP) or the D, antagonist raclopride (0.1 or 1.0 mg/kg, IP) supp

Effect of the putative dopamine D1 agoni
โœ L. Verhagen Metman; P. J. Blanchet; D. de Jong; M. M. Mouradian; Dr. T. N. Chase ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 433 KB

## Abstract The ergoline derivative FCE 23884 acts as a dopamine D~1~ agonist in untreated parkinsonian animals and as a D~2~ antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have